Company intelligence / Profile preview

GlySens

San Diego, California, United Statesglysens.com ↗

Ownership: Private
Development stage: Phase 1

Overview

GlySens has demonstrated clinical feasibility of its fully implanted continuous glucose monitoring system in multiple patients for up to 12 months, with preclinical data showing sensor lifetimes up to 18 months. Ongoing and completed clinical trials support safety and performance claims. The third-generation Eclipse 3 ICGM system is undergoing first-in-man studies as of Q1 2021.

Therapeutic areas: Endocrinology
Modalities: DeviceSensor (Implantable medical device)
Industry: Physiological Monitoring

Drug pipeline

2 assets

Eclipse ICGM System

Phase 1

Indications: Diabetes

1 more asset in the full pipeline.

Request access →

Partnerships

McNair Interests (investor/supporter)The Sarofim Group (investor/supporter)

Beyond the preview

Go deeper on GlySens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlySens.

Explore the full profile